AstraZeneca is withdrawing its highly successful COVID-19 vaccine, citing the availability of a plethora of new shots that led to a decline in demand. The vaccine — called Vaxzevria and developed in partnership with the University of Oxford — has been one of the main COVID-19 vaccines worldwide, with more than three billion doses supplied since the first was administered in the UK on January 4, 2021. But the vaccine has not generated revenue for AstraZeneca since April 2023, the company said.
Thus, they form a key part of most countries’ longer-term strategies.” Vaccine timeline The UK-based pharmaceutical firm, known for its popular cancer drugs, entered the COVID-19 crisis with little experience developing vaccines. And the success of Vaxzevria was far from guaranteed.